Compared with ranibizumab, MP0112 has greater binding affinity to VEGF-A and is retained in the vitreous for a substantially longer time.23 The evidence suggests, therefore, that MP0112 has the potential to reduce the frequency of intravitreal injections. A recent study has demonstrated the potential of DARPins compared with currently available agents in DME.23 The current study was designed to assess the safety, tolerability and preliminary efficacy of intravitreal injections of MP0112 for the treatment of exudative

AMD and was performed in parallel with the DME study. This phase I/II, open-label, noncontrolled, dose-escalation trial was conducted in 8 ophthalmologic centers in France, Cabozantinib ic50 Switzerland and the Czech Republic. The study and data accumulation were Y-27632 in vitro carried out with approval from the following ethics committees: CPP Ile de France III, Kantonale Ethikkommission Bern, Ethics Committee of Central Military Hospital, Ethics

Committee of Faculty Hospital Brno, and Ethics Committee of Faculty Hospital Olomouc. The study adhered to the guidelines of the Declaration of Helsinki, and the protocol and consent forms were approved by a local investigational review board. Each subject provided written consent to participate in this research study. The study is registered at ClinicalTrials.gov under the identifier: NCT01086761. Male and female patients 50 years of age or older who had clinical signs and angiographic evidence of active primary progressive subfoveal CNV, including juxtafoveal lesions that affected the fovea on

fluorescein angiography (FA) in the study eye and that were at least 50% of the total lesion area, were eligible for enrollment. Patients were also required to meet the Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) of 70 to 25 letters (Snellen equivalent of 20/40 to 20/320) in the study eye at 4 meters. Patients with any of the following were excluded from the study: any prior treatment for neovascular AMD in the study Rolziracetam eye; a total lesion size of >20 mm2; subretinal hemorrhage either ≥50% of the total lesion area or with ≥2.54 mm2 blood under the fovea; scar or fibrosis ≥50% of the total lesion in the study eye; or scar, fibrosis or atrophy involving the center of the fovea. Patients with other causes of CNV or ocular surgery (including cataract extraction) in the study eye within 3 months of enrollment were also not eligible to participate. The primary study objective was to assess the safety and tolerability of intravitreal doses of MP0112. Secondary objectives were to assess the preliminary efficacy of MP0112 based on changes in BCVA, central retinal thickness (CRT) as measured by optical coherence tomography (OCT), and CNV leakage as measured by FA.